Business Context and Reporting Period
This Form 6-K filing by Clearmind Medicine Inc. covers the month of May 2026, with the report dated May 19, 2026. The filing details a specific corporate action regarding the conversion of convertible promissory notes under existing securities purchase agreements (SPAs) entered into on September 17, 2025, and amended on April 30, 2026.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The specific financial activity reported is as follows:
- Debt Conversion: Two CLA Investors converted an aggregate principal amount of $600,000 under Promissory Notes.
- Conversion Price: The conversion was executed at an agreed price of $0.30 per common share.
- Capital Structure Adjustment: The floor price for Promissory Notes attached to the SPAs was amended to $0.30 per common share.
- Liquidity: The filing references prior cash proceeds from note issuances in February and May 2026 (90% of principal), but does not report current cash balances or liquidity ratios.
Material Changes
The primary material change reported is the execution of a Conversion Agreement on May 19, 2026. This action reduces the outstanding principal of the Promissory Notes by $600,000 and increases the company's share count based on the $0.30 conversion price. Additionally, the amendment to the floor price in the SPAs represents a change in the terms governing future potential issuances under the agreement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard incorporation by reference to the full text of the Conversion Agreement (Exhibit 99.1). The document focuses strictly on the mechanics of the debt-to-equity conversion and the amendment of the floor price.
Investor Verification Checklist
- Verify the exact number of common shares issued upon the conversion of the $600,000 principal at $0.30 per share.
- Confirm the remaining aggregate principal amount available under the $10,000,000 SPA facility after this conversion.
- Review the full text of the Conversion Agreement (Exhibit 99.1) for any additional covenants or conditions not summarized in the filing.
- Assess the impact of the amended $0.30 floor price on future dilution potential under the SPAs.